A novel method for detecting the analgesic effect of drugs by quantifying body movement after noxious stimulation in neonatal rat

Effects of opioid receptor and alpha2-adrenoceptor agonists on slow ventral root potentials and on capsaicin and formalin tests in neonatal rats

The inhibitory effects of morphine and alpha2-adrenoceptor agonists on slow ventral root potentials (slow VRP) following ipsilateral dorsal root stimulation in neonatal rat spinal cord were compared with the analgesic effects of these drugs on formalin and capsaicin tests in neonatal rats. Morphine, (D-Phe2, D-Pen5)-enkephalin (DPDPE), dexmedetomidine, clonidine and xylazine showed concentration-related inhibition of slow VRP. The order of potency was dexmedetomidine>morphine=DPDPE>clonidine>xylazine. The inhibitory effects of opioid agonists and alpha2-adrenoceptor agonists were abolished by naloxone, an opioid antagonist, and atipamezole, an alpha2-adrenoceptor antagonist, respectively. There was no cross antagonism. Morphine, dexmedetomidine and xylazine dose-dependently inhibited body movement induced by formalin or capsaicin. The order of potency was dexmedetomidine>morphine>xylazine. Although morphine and dexmedetomidine inhibited formalin- and capsaicin-induced body movement in the same dose range, xylazine inhibited formalin-induced body movement at lower concentrations than capsaicin-induced one. The inhibitory potency for slow VRP by these drugs seems to be correlated with that for capsaicin-induced body movement but not that for formalin-induced one. Dexmedetomidine and morphine in combination inhibited slow VRP and body movement induced by capsaicin in an additive manner. It is suggested that the antinociceptive effects of dexmedetomidine and morphine but not xylazine on the capsaicin test are mainly due to spinal effects and that there is no synergistic interaction between dexmedetomidine and morphine in the neonatal rat.

Endogenous opiates: 1998

This paper is the twenty-first installment of our annual review of research concerning the opiate system. It summarizes papers published during 1998 that studied the behavioral effects of the opiate peptides and antagonists, excluding the purely analgesic effects, although stress-induced analgesia is included. The specific topics covered this year include stress; tolerance and dependence; eating and drinking; alcohol; gastrointestinal, renal, and hepatic function; mental illness and mood; learning, memory, and reward; cardiovascular responses; respiration and thermoregulation; seizures and other neurologic disorders; electrical-related activity; general activity and locomotion; sex, pregnancy, and development; immunologic responses; and other behaviors.

Pharmacological characterization of capsaicin-induced body movement of neonatal rat

In neonatal rats, nociceptive responses induced by capsaicin were characterized pharmacologically. Capsaicin, injected subcutaneously (s.c.), induced body movement including scratching and struggling responses, and the responses were quantified by using a device composed of an audio speaker as a detector. The capsaicin-induced body movement was inhibited by a tachykinin NK1-receptor antagonist RP-67580 with an ID50 value of 3.5 mg/kg, s.c. Opioid analgesics, morphine, buprenorphine and pentazocine, also inhibited the body movement with ID50 values of 0.085, 0.0079 and 0.92 (mg/kg, s.c.), respectively. Non-steroidal anti-inflammatory drugs, indomethacin, ibuprofen and acetaminophen, did not exert any effect on the capsaicin-induced body movement. Neither the sedative diazepam nor the sedative chlorpromazine inhibited the body movement. It is concluded that the capsaicin-induced body movement in neonatal rats, which is considered to be nociceptive responses mediated by substance P, is sensitive to centrally acting analgesics with micro-opioid receptor agonist activity.